Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Eli Lilly And Co (NYSE:LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on February 6 ...

A woman's hands star in a Lilly spot, shown playing key role in activities like gardening -- and discovering a lump in her ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...

Eli Lilly already has market share in the breast cancer space with the approved drug Verzenio (abemaciclib), and is advancing investigational drugs like the oral selective estrogen receptor degrader ...

Eli Lilly and Company discovers ... Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and ...

cancer drug Verzenio, and fast-acting insulin Humalog. And that's before we get into the company's pipeline, which features plenty of investigational drugs beyond Eli Lilly's core area of diabetes ...